1 2	State of Arkansas 93rd General Assembly	$\overset{As\ Engrossed:\ H2/24/21}{ ext{A}\  ext{Bill}}$	
3	Regular Session, 2021		HOUSE BILL 1247
4	,		
5	By: Representative Gonzale	es	
6			
7		For An Act To Be Entitled	
8	AN ACT TO MODIFY PHYSICIAN DISPENSING; TO ALLOW		
9	DELEGATION OF PHYSICIAN DISPENSING; AND FOR OTHER		
10	PURPOSES		
11			
12			
13		Subtitle	
14	то	MODIFY PHYSICIAN DISPENSING; AND TO	
15	ALL	OW DELEGATION OF PHYSICIAN DISPENSING	•
16			
17			
18	BE IT ENACTED BY THE	GENERAL ASSEMBLY OF THE STATE OF ARKA	NSAS:
19			
20	SECTION 1. Arl	kansas Code § 17-95-102 is amended to	read as follows:
21	17-95-102. Leg	gend drugs.	
22	(a) <del>A dispens</del>	<del>ing physician is</del> <u>As used in this secti</u>	on, a "dispensing
23	<u>physician" means</u> a pl	hysician licensed under the Arkansas M	ledical Practices
24	Act, § 17-95-201 et s	seq.,  17-95-301 et seq., and  17-95	-401 et seq., who
25	purchases legend drug	gs to be dispensed to his or her patie	nts for the
26	patients' personal us	se and administration outside the phys	ician's office.
27		ion <del>shall</del> <u>does</u> not apply to physicians	
28	drugs in injectable form unless they are controlled substances, in which case		
29	the section shall ful	lly apply.	
30	(c) The disper	nsing physician shall:	
31	(1) Pers	sonally dispense legend drugs, and the	e dispensing of such
32	drugs may <del>not</del> be dele	egated;	
33		Keep records of all receipts and distr	ibutions of legend
34	drugs.		
35	<u>(B)</u>		-
36	nroner enforcement as	uthority and chall he readily accessib	la for inchaction

1 and maintained in a central registry; and 2 (3) Label legend drugs with the following information: 3 (A) Patient's name and address; 4 (B) Prescribing physician's address and narcotic registry 5 number issued by the United States Drug Enforcement Administration; 6 (C) Date of dispensing; and 7 (D) Directions and cautionary statements, if any, as 8 required by law. 9 (d)(1) A physician licensed under the Arkansas Medical Practices Act, 10 § 17-95-201 et seq., § 17-95-301 et seq., and § 17-95-401 et seq., shall not 11 dispense legend drugs without prior approval by the Arkansas State Medical 12 Board after application to the board and on the showing of need. (2) Licensed physicians who were dispensing in the ordinary 13 14 course of their practice before April 12, 2013, shall be exempt from the 15 requirements of this subsection. 16 (3) The board shall determine whether need exists for a 17 physician to dispense a specific legend drug to the physician's patient for a 18 patient's personal use and administration outside of the physician's office 19 based on such information as is necessary for the board to determine: 20 The legend drug or drugs that the physician requests 21 to dispense; 22 (B) The ability of a physician's patient to obtain the 23 legend drug from other medical professionals; 24 The availability of the legend drug to be prescribed (C) 25 by the physician; 26 (D) The hours at which the legend drug may be obtained 27 from other medical professionals; 28 The distance the physician's patient must travel to 29 obtain the legend drug from other medical professionals; 30 (F)Whether the physician has been investigated by the 31 board concerning the improper prescribing or use of a legend drug; 32 Whether the physician has a financial relationship 33 with the manufacturer of a legend drug that would create the appearance of a

(H) Whether the physician dispensing a legend drug will foster cost containment through improved efficiency and productivity; and

HB1247

conflict of interest;

3435

36

1	(I) The procedures the physician has implemented to:		
2	(i) Assure compliance with the requirements of		
3	subsection (c) of this section;		
4	(ii) Monitor and guard against potential drug		
5	interactions;		
6	(iii) Store and safeguard the legend drugs; and		
7	(iv) Comply with the Prescription Drug Monitoring		
8	Program Act, § 20-7-601 et seq., concerning the reporting requirements to the		
9	Prescription Drug Monitoring Program.		
10	(4) This section does not apply to a prescription for:		
11	(i) A prescription for a topical medication;		
12	<u>(ii)</u> Naloxone <del>,</del> ;		
13	(iii) Nicotine nicotine replacement therapy		
14	products <del>, or</del> ;		
15	(iv) Contraceptives; contraceptives is exempt from		
16	subdivision (d)(3) of this section		
17	(v) Acute care medication; or		
18	(vi) Initial treatment for maintenance medication.		
19	(e) The <del>board</del> <u>Arkansas State Medical Board</u> shall enforce the		
20	provisions of this section and is authorized and directed to adopt rules to		
21	carry out its purpose the purpose of this section.		
22	(f) As used in this section:		
23	(1)(A) "Acute care medication" means a legend drug that is not a		
24	controlled substance and is prescribed for no more than fourteen (14) days of		
25	<u>therapy.</u>		
26	(B) "Acute care medication" includes the following oral		
27	medications:		
28	(i) Medications to treat infections;		
29	(ii) Anti-inflammatory medications;		
30	(iii) Antinausea medications;		
31	(iv) Antihistamines; and		
32	(v) Cough medications;		
33	(2) "Initial treatment" means the first prescription written for		
34	a specific prescription medication intended to initiate therapy on such		
35	medication; and		
36	(3) "Maintenance medication" means a legend drug that:		

As Engrossed: H2/24/21

HB1247

1	1 <u>(A) Is no</u>	t a controlled substance;
2	2 <u>(B)</u> Is pr	escribed for no more than thirty (30) days; and
3	3 <u>(C)</u> Is us	ed to treat one (1) of the following medical
4	4 <u>conditions:</u>	
5	5 <u>(i)</u>	Hypertension;
6	6 <u>(ii)</u>	Diabetes mellitus; or
7	7 <u>(iii</u>	) Hypercholesterolemia.
8	8	
9	9	/s/Gonzales
10	0	
11	1	
12	2	
13	3	
14	4	
15	5	
16	6	
17	7	
18	8	
19	9	
20	0	
21	1	
22	2	
23	3	
24	4	
25	5	
26	6	
27		
28		
29		
30		
31		
32		
33		
34		
35		
36	6	